Nutex Health, INC 8-K filings

A Fifth Circuit Court of Appeals ruling vacates key portions of a rule impacting the No Surprises Act, potentially increasing reimbursement rates for healthcare providers like Nutex Health.

Nutex Health Inc. has amended its Payment Dispute Resolution Services Agreement with HaloMD, L.L.C., changing the fee structure and extending the agreement term.

Nutex Health Inc. announced the results of its annual meeting of stockholders held on April 23, 2026, where all seven director nominees were elected and executive compensation was approved.

Nutex Health Inc. announced robust full-year 2025 financial results with significant revenue and profit growth, alongside a new $25 million stock repurchase program, despite a challenging fourth quarter.

Nutex Health Inc. filed an auditor's consent for the incorporation by reference of financial reports into several Form S-8 registration statements.

Nutex Health Inc. announced significantly improved financial and operating results for the third quarter and first nine months of 2025, marked by substantial revenue and profit growth.

Nutex Health Inc. announced significant revenue and Adjusted EBITDA growth for the first half of 2025, alongside a new $25 million stock repurchase program.

Nutex Health restated Q1 2025 results show a sharp swing to profitability, 214% revenue growth, record operating cash flow, and higher EPS after non-cash reclassifications.

Nutex Health Inc. announced significantly improved restated financial results for 2024, reporting substantial revenue growth and a shift from net loss to net income, despite minor non-cash adjustments.

Nutex Health Inc. reported significant year-over-year growth in patient volume and cash collections for Q3 2025, while also addressing Nasdaq non-compliance due to delayed financial filings and restatement of prior financials.

Nutex Health Inc. announced the appointment of Wesley Bamburg, an experienced healthcare executive, as its new Chief Operating Officer, effective October 13, 2025.

Nutex Health Inc. is facing a derivative lawsuit filed by a stockholder alleging breaches of fiduciary duties, gross mismanagement, and other claims against its top executives and board members.

Nutex Health Inc. announced the appointment of Michael L. Reed as its Lead Independent Director, effective September 2, 2025, enhancing corporate governance.

Nutex Health Inc. announced a securities class action lawsuit has been filed against the company and its executives, alleging violations of the Exchange Act.

Nutex Health announced a restatement of prior financial statements, received a Nasdaq delisting notice for delayed Q2 2025 filing, and reported strong preliminary Q2 2025 financial results amidst ongoing legal and short-seller challenges.

Nutex Health Inc. announced preliminary strong second-quarter financial results, a new $25 million stock repurchase program, and a delay in its Form 10-Q filing due to non-cash accounting adjustments.

Nutex Health Inc. stockholders approved the election of seven director nominees, advisory executive compensation, and an amendment to the 2023 Equity Incentive Plan at their annual meeting on July 14, 2025.

Nutex Health Inc. announced the resignation of its Chief Operating Officer, Joshua DeTillio, effective August 8, 2025, as he departs to assume a Chief Executive Officer position at another company.

Nutex Health Inc. dismisses CBIZ CPAs P.C. and appoints Grant Thornton LLP as its new independent registered public accounting firm, citing material weaknesses in internal controls.

Nutex Health Inc. announces a significant increase in revenue and profitability for the first quarter of 2025, driven by arbitration efforts and operational improvements.

Nutex Health Inc. reports the resignation of Marcum LLP as its independent auditor due to its acquisition by CBIZ CPAs P.C., and the subsequent engagement of CBIZ as the new auditor.

Nutex Health announces a significant turnaround in 2024, reporting substantial revenue growth and profitability driven by successful arbitration efforts.

Nutex Health reports positive outcomes from its No Surprises Act (NSA) arbitration strategy, achieving an over 80% success rate in Q4 2024.

Nutex Health announced a 25% increase in revenue for the first nine months of 2024, alongside significant improvements in operating income and adjusted EBITDA.

Nutex Health announced a 29% increase in revenue and significant improvements in profitability for the second quarter of 2024, driven by growth in both hospital visits and mature hospital performance.

Nutex Health has regained compliance with Nasdaq listing rules after its stock price traded above $1.00 per share following a 1:10 reverse stock split.

Nutex Health has completed a 1-for-10 reverse stock split, effective July 2, 2024, following shareholder approval at the annual meeting.

Nutex Health has received an extension from Nasdaq until July 22, 2024, to regain compliance with the $1.00 minimum bid price requirement through a reverse stock split.

Nutex Health Inc. is facing potential delisting from the Nasdaq Stock Market after failing to maintain the minimum bid price requirement, and has requested a hearing to appeal the decision.

Nutex Health announced a 20% increase in total revenue and a significant improvement in profitability for the first quarter of 2024.